Bod Science (ASX:BOD) ROC (Joel Greenblatt) %: 27,500.00% (As of Jun. 2025)


ASX:BOD Bod Science Ltd ASX:BOD
12 GF Score
Price A$0.02
GF Value A$0.04
! 3 Warning Signs
View Full Analysis

What is Bod Science ROC (Joel Greenblatt) %?

Bod Science ASX:BOD 12 ROC (Joel Greenblatt) % is 27,500.00% as of Jun. 2025. GuruFocus rates ASX:BOD with a GF Score™ of 12/100 and a GF Value™ of A$0.04. The stock has 3 warning signs investors should review.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bod Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 27,500.00%.

The historical rank and industry rank for Bod Science's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:BOD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17613.33   Med: -12084.62   Max: 7063.64
Current: 7063.64

During the past 9 years, Bod Science's highest ROC (Joel Greenblatt) % was 7063.64%. The lowest was -17613.33%. And the median was -12084.62%.

ASX:BOD's ROC (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 11.45 vs ASX:BOD: 7063.64

Bod Science's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Bod Science  (ASX:BOD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Bod Science ROC (Joel Greenblatt) % Related Terms


Bod Science ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Bod Science's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bod Science ROC (Joel Greenblatt) % Chart

Bod Science Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -3,893.63 -5,746.03 -17,613.33 -15,397.56 6,500.00

Bod Science Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,121.70 -13,775.00 -929.63 -640.00 27,500.00

ASX:BOD vs ZTS: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bod Science ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bod Science's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Bod Science's ROC (Joel Greenblatt) % falls into.


ASX:BOD
12GF Score
Bod Science Ltd ASX:BOD
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bod Science ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.218 + 0.344 + 0.154) - (4.714 + 0 + 0.283)
=-4.281

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.168 + 0.408 + 0.549) - (5.814 + 0 + 0.275)
=-4.964

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Bod Science for the quarter that ended in Jun. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.55/( ( (0.003 + max(-4.281, 0)) + (0.001 + max(-4.964, 0)) )/ 2 )
=0.55/( ( 0.003 + 0.001 )/ 2 )
=0.55/0.002
=27,500.00 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 27,500.00% mean?
Bod Science (ASX:BOD) has a ROC (Joel Greenblatt) % of 27,500.00% as of Jun. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bod Science and its competitors.
Is Bod Science's ROC (Joel Greenblatt) % too high?
Bod Science's current ROC (Joel Greenblatt) % is 27,500.00%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Bod Science's value of 27,500.00% is 240074.7% above this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's ROC (Joel Greenblatt) % compare to ZTS?
Bod Science's ROC (Joel Greenblatt) % of 27,500.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROC (Joel Greenblatt) % is 11.45. Bod Science's value of 27,500.00% is 240074.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current ROC (Joel Greenblatt) % of 27,500.00% is 240074.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current ROC (Joel Greenblatt) % is 27,500.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current ROC (Joel Greenblatt) % of 27,500.00%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current ROC (Joel Greenblatt) % is 27,500.00% and 240074.7% above the Drug Manufacturers industry median of 11.45. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current ROC (Joel Greenblatt) % is 27,500.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bod Science (ASX:BOD) Overvalued in 2026?

Based on GuruFocus' analysis, Bod Science stock appears to be undervalued. The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.

Key valuation signals for ASX:BOD:

  • ROC (Joel Greenblatt) %: 27,500.00%
  • GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
  • GF Score™: 12/100 with 3 warning signs
  • Industry Position: 240074.7% above the Drug Manufacturers median

No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bod Science Business Description

Address C/- Rodgers Reidy, 210 Clarence Street, Level 12, Sydney, NSW, AUS, 2000
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score

Get the complete analysis for ASX:BOD

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.02
Price
A$0.04
GF Value